Extremity and Truncal Soft Tissue Sarcoma: Risk Assessment and Multidisciplinary Management

Area of Science:

• Oncology
• Surgical Oncology
• Cancer Research

Background:

• Extremity and truncal soft tissue sarcomas are rare, heterogeneous cancers originating from mesenchymal tissues.
• Effective management necessitates tailored risk assessment and prognostication tools for optimal treatment selection.
• Multidisciplinary strategies have significantly advanced in recent decades for managing these tumors.

Purpose of the Study:

• To highlight the importance of tailored risk assessment and prognostication in soft tissue sarcoma management.
• To emphasize the critical role of a multidisciplinary approach in optimizing treatment strategies.
• To review current therapeutic modalities for extremity and truncal soft tissue sarcomas.

Main Methods:

• Review of current literature and clinical practice guidelines for soft tissue sarcoma management.
• Emphasis on the integration of surgical, loco-regional, and systemic therapies.
• Discussion of risk stratification and prognostication tools.

Main Results:

• Surgery is the primary treatment, aiming for negative microscopic tumor margins.
• Loco-regional treatments (radiation therapy, isolated limb perfusion) combined with surgery reduce local recurrence and enable limb-sparing procedures.
• Chemotherapy can further decrease local recurrence and distant metastasis in select patients.

Conclusions:

• Optimal treatment selection for rare soft tissue sarcomas is best achieved through an experienced multidisciplinary team.
• A combined approach utilizing surgery, radiation, and potentially chemotherapy offers the best outcomes.
• Personalized risk assessment is key to tailoring treatment strategies for improved patient prognosis.